Cougar Biotechnology Inc., of Los Angeles, added $50 million in private funding for ongoing development of its three drug candidates, including one for prostate cancer expected to enter Phase III within the next year. The firm agreed to sell 2.5 million shares of its common stock in a private placement priced at $20 per share. The offering is expected to close May 8. Proceeds from the offering, based on analyst reports, should "get us out …
No comments:
Post a Comment